Supernus Pharmaceuticals Stock Performance
| SUPN Stock | USD 38.69 0.31 0.79% |
On a scale of 0 to 100, Supernus Pharmaceuticals holds a performance score of 8. The entity has a beta of 0.34, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Supernus Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Supernus Pharmaceuticals is expected to be smaller as well. Please check Supernus Pharmaceuticals' potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to make a quick decision on whether Supernus Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Supernus Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Supernus Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.79) | Five Day Return 0.81 | Year To Date Return 6.2 | Ten Year Return 358.41 | All Time Return 620.48 |
1 | Disposition of 125000 shares by Jack Khattar of Supernus Pharmaceuticals at 9.13 subject to Rule 16b-3 | 11/07/2024 |
2 | Supernus Pharmaceuticals director sells shares worth 520,480 | 11/08/2024 |
3 | Disposition of 20000 shares by Newhall Charles W Iii of Supernus Pharmaceuticals at 9.13 subject to Rule 16b-3 | 11/11/2024 |
4 | 56,885 Shares in Supernus Pharmaceuticals, Inc. Bought by State of New Jersey Common Pension Fund D - MarketBeat | 11/19/2024 |
5 | Supernus Pharmaceuticals, Inc. Shares Acquired by Pacer Advisors Inc. - MarketBeat | 11/22/2024 |
6 | Disposition of 8750 shares by Padmanabh Bhatt of Supernus Pharmaceuticals at 23.99 subject to Rule 16b-3 | 12/03/2024 |
7 | Ashford Capital Management Inc. Has 16.96 Million Position in Supernus Pharmaceuticals, Inc. - MarketBeat | 12/10/2024 |
8 | Newron and EA Pharma Announce License Agreement for Evenamide in Japan and Other Asian Territories | 12/13/2024 |
9 | Disposition of 10000 shares by Gemayel Georges of Supernus Pharmaceuticals at 31.33 subject to Rule 16b-3 | 12/18/2024 |
10 | Acquisition by Jonathan Rubin of 750 shares of Supernus Pharmaceuticals subject to Rule 16b-3 | 12/23/2024 |
11 | Disposition of 14000 shares by Jack Khattar of Supernus Pharmaceuticals subject to Rule 16b-3 | 12/27/2024 |
12 | Disposition of 20000 shares by Hudson Frederick M. of Supernus Pharmaceuticals at 9.13 subject to Rule 16b-3 | 01/22/2025 |
13 | Disposition of 2573 shares by Padmanabh Bhatt of Supernus Pharmaceuticals at 29.61 subject to Rule 16b-3 | 01/27/2025 |
14 | Supernus Pharmaceuticals exec sells 129,676 in stock - Investing.com | 01/29/2025 |
| Begin Period Cash Flow | 93.1 M |
Supernus |
Supernus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 3,470 in Supernus Pharmaceuticals on November 2, 2024 and sell it today you would earn a total of 399.00 from holding Supernus Pharmaceuticals or generate 11.5% return on investment over 90 days. Supernus Pharmaceuticals is currently generating 0.2004% in daily expected returns and assumes 1.8064% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of stocks are less volatile than Supernus, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Supernus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Supernus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Supernus Pharmaceuticals, and traders can use it to determine the average amount a Supernus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1109
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SUPN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.81 actual daily | 16 84% of assets are more volatile |
Expected Return
| 0.2 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Supernus Pharmaceuticals is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Supernus Pharmaceuticals by adding it to a well-diversified portfolio.
Supernus Pharmaceuticals Fundamentals Growth
Supernus Stock prices reflect investors' perceptions of the future prospects and financial health of Supernus Pharmaceuticals, and Supernus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Supernus Stock performance.
| Return On Equity | 0.0622 | ||||
| Return On Asset | 0.0289 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 1.79 B | ||||
| Shares Outstanding | 55.22 M | ||||
| Price To Earning | 15.25 X | ||||
| Price To Book | 2.14 X | ||||
| Price To Sales | 3.28 X | ||||
| Revenue | 607.52 M | ||||
| Gross Profit | 580.54 M | ||||
| EBITDA | 90.04 M | ||||
| Net Income | 1.32 M | ||||
| Cash And Equivalents | 360.79 M | ||||
| Cash Per Share | 6.74 X | ||||
| Total Debt | 41.53 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 0.85 X | ||||
| Book Value Per Share | 18.24 X | ||||
| Cash Flow From Operations | 111.08 M | ||||
| Earnings Per Share | 1.07 X | ||||
| Market Capitalization | 2.14 B | ||||
| Total Asset | 1.28 B | ||||
| Retained Earnings | 482.56 M | ||||
| Working Capital | 202.92 M | ||||
| Current Asset | 105.95 M | ||||
| Current Liabilities | 56.93 M | ||||
About Supernus Pharmaceuticals Performance
By examining Supernus Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Supernus Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Supernus Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 387.83 | 368.44 | |
| Return On Capital Employed | 0.00 | (0.01) |
Things to note about Supernus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Supernus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Supernus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Supernus Pharmaceuticals currently holds 41.53 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Supernus Pharmaceuticals has a current ratio of 0.83, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Supernus Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Over 95.0% of Supernus Pharmaceuticals shares are owned by institutional investors | |
| Latest headline from news.google.com: Supernus Pharmaceuticals exec sells 129,676 in stock - Investing.com |
- Analyzing Supernus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Supernus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Supernus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Supernus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Supernus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Supernus Pharmaceuticals' stock. These opinions can provide insight into Supernus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share | Quarterly Revenue Growth 0.142 | Return On Assets |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.